Amrubicin-Induced Radiation Recall Pneumonitis After Low-Dose Palliative Thoracic Radiotherapy: A Case Report
- 1Department of Respiratory Internal Medicine, Fukui Prefectural Hospital, Fukui, JPN
Abstract
A 70-year-old man with extensive-stage small-cell lung cancer received palliative thoracic radiotherapy to a total dose of 18 Gy in six fractions for central airway stenosis. Five months later, second-line amrubicin was initiated. After two courses of treatment, he was admitted with fever and cough and was initially treated for suspected bacterial pneumonia. Despite cefepime treatment, computed tomography revealed worsening pulmonary opacities corresponding to the previously irradiated field. Bronchoscopy showed no visible endobronchial tumor, cytology revealed no malignant cells, and microbiological studies were negative. Amrubicin-induced radiation recall pneumonitis (RRP) was clinically diagnosed. Amrubicin was discontinued, and oral prednisolone was initiated at 30 mg/day, resulting in rapid clinical and radiographic improvement. Prednisolone was subsequently tapered to 10 mg/day without radiographic worsening at that dose. This case highlights that RRP should be considered after amrubicin therapy, even when the previous thoracic radiation dose was relatively low.
Related
- The Impact of Idiopathic Pulmonary Fibrosis on the Incidence and Severity of Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Following Radiotherapy
- Hemostatic Response to Palliative Radiotherapy for Bleeding Gastric Cancer and Pretreatment Endoscopic Characteristics: A Retrospective Cohort Study
- Incremental Value of Radiation Dose for Prognostic Stratification Beyond Performance Status in Palliative Radiation Therapy for Bone Metastases
- AI-assisted 3D thoracic body composition analysis identifies candidate imaging markers associated with overall survival in older patients with lung cancer receiving radiotherapy
- Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study
BibTeX
@article{fujii2026amrubicininduced,
title = {{Amrubicin-Induced Radiation Recall Pneumonitis After Low-Dose Palliative Thoracic Radiotherapy: A Case Report}},
author = {Yuya Fujii and Kaisei Iwamoto and Ryosuke Kojima and Shinichi Nakanishi and Riki Matsukawa},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117848},
url = {https://doi.org/10.7759/cureus.117848},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Amrubicin-Induced Radiation Recall Pneumonitis After Low-Dose Palliative Thoracic Radiotherapy: A Case Report
AU - Yuya Fujii
AU - Kaisei Iwamoto
AU - Ryosuke Kojima
AU - Shinichi Nakanishi
AU - Riki Matsukawa
PY - 2026
DA - 2026/10/13
JO - Cureus
DO - 10.7759/cureus.117848
UR - https://doi.org/10.7759/cureus.117848
AB - A 70-year-old man with extensive-stage small-cell lung cancer received palliative thoracic radiotherapy to a total dose of 18 Gy in six fractions for central airway stenosis. Five months later, second-line amrubicin was initiated. After two courses of treatment, he was admitted with fever and cough and was initially treated for suspected bacterial pneumonia. Despite cefepime treatment, computed tomography revealed worsening pulmonary opacities corresponding to the previously irradiated field. Bronchoscopy showed no visible endobronchial tumor, cytology revealed no malignant cells, and microbiological studies were negative. Amrubicin-induced radiation recall pneumonitis (RRP) was clinically diagnosed. Amrubicin was discontinued, and oral prednisolone was initiated at 30 mg/day, resulting in rapid clinical and radiographic improvement. Prednisolone was subsequently tapered to 10 mg/day without radiographic worsening at that dose. This case highlights that RRP should be considered after amrubicin therapy, even when the previous thoracic radiation dose was relatively low.
SN - 2168-8184
ER -